T he field of cardiovascular imaging has been searching for the ideal imaging technique that will quantitatively and reliably assess vulnerable coronary plaques and also assess for cardiovascular risk noninvasively. Myocardial infarction (MI), a consequence of coronary atherosclerosis, remains the leading cause of death in the Western world despite advances in pathophysiology. 1 The development of novel therapies to treat vascular disease beyond current treatment recommendations remains slow, in part, because of the high cost of conducting cardiovascular outcome trials and the challenge of demonstrating that a novel therapy has effects on atherosclerotic plaques that translate into MI reduction if advanced into a large outcomes study. 
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Recently, many studies have demonstrated that fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) accurately identifying regions of arterial inflammation in vivo, which can be reliably assessed longitudinally after an intervention. Within this large body of work, fluorodeoxyglucose PET/CT arterial inflammation estimates current cardiovascular risk, 3 relates to severity of inflammatory diseases, 4 and is prognostic of future cardiovascular events. 5, 6 Specifically, higher uptake in the carotid arteries was related to the occurrence of stroke in the future. 6 Fluorodeoxyglucose uptake in the aorta has been associated with increased risk for future MI. 5 Higher areas of fluorodeoxyglucose uptake were associated with experiencing the MI sooner than those with lower uptake. 5 Finally, fluorodeoxyglucose uptake in the artery modulates with interventions known to be of benefit in cardiovascular outcomes trials. For example, the use of statin therapy was associated with a reduction of arterial inflammation at 12 weeks, 7, 8 and therapeutic lifestyle changes over the course of 6 months led to a decrease in arterial inflammation. 9 Most of these studies utilized arterial inflammation measured in the aorta or the carotid arteries, and few studies have attempted to measure arterial inflammation directly in the coronary arteries using fluorodeoxyglucose PET/CT. Development of this measurement to assess left main coronary artery (LMCA) inflammation has likely been hampered by the inherent spatial resolution limitation of PET (4 mm) and myocardial uptake of fluorodeoxyglucose. This latter issue although can be overcome with a diet-based intervention of high-fat low-carbohydrate food content before the study.
In this issue of Circulation: Cardiovascular Imaging, Singh et al 10 use fluorodeoxyglucose PET CT to assess arterial inflammation in the LMCA in addition to the carotid arteries. 10 The study was performed in a subset of patients who were part of a prospective study of statin effects on arterial inflammation. To enter the study, participants had to have a target/background ratio of >1.6 on fluorodeoxyglucose PET CT in the carotid arteries. After a myocardial suppression protocol to reduce fluorodeoxyglucose uptake in the heart, the authors quantified arterial inflammation in the proximal portion of the LMCA. Specifically, 4 regions of interest were placed: at the LMCA ostium, 5 and 10 mm distally, and that at the LM bifurcation. These 4 values of maximal fluorodeoxyglucose uptake were averaged to produce a single value. Then, participants underwent coronary CT angiography to perform luminography and assessment of plaque morphology in the coronary arteries for high-risk features. Techniques to identify high-risk plaque included the presence of non-or partially calcified plaque and positive remodeling. These approaches are well accepted in the field and have been shown to be predictive of future cardiovascular events. 11 In an exploratory analysis, the authors also performed inflammatory biomarker phenotyping to probe mechanism associated with potential improvement of arterial inflammation after therapy. The overall study design permitted the authors to assess relationships between LMCA arterial inflammation detected by fluorodeoxyglucose PET/CT, highrisk plaque assessed by coronary CT angiography, and the effect of statin therapy in double-blinded, active comparator trial.
Seventy-one patients, previously on either no dose or low-dose statins completed the 12-week study period after randomization to atorvastatin 10 versus 80 mg. Of these, 68 had PET/CT images of high quality, and within this group, 55 had CTA images of high enough quality for analysis. First, the authors found that LMCA inflammation was ≈15% higher in The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.
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Correspondence to Nehal N. In their exploratory analysis with serum biomarkers, the author reports that higher high-sensitivity C-reactive protein was associated with high-risk plaque morphology, but not with LMCA inflammation. Furthermore, they report a weak correlation between LMCA inflammation and matrix metalloproteinase-3 (r=0.42; P=0.04). Perhaps one of the most interesting findings of the study was that there was a strong correlation between LMCA inflammation and target/background ratio in extracoronary vessels, with the aorta being the strongest correlate (r=0.6; P<0.001) and carotids being the weakest (r=0.32; P=0.04). Strikingly, there was a strong association observed between extracoronary arterial inflammation and coronary high-risk plaque. This finding particularly suggests the robust quality of risk data assessed by aortic vascular inflammation and supports findings that aortic vascular inflammation increases the risk for future MI. 5 Furthermore, they found that after statin therapy, the decrease in LMCA arterial inflammation correlated with changes in extracoronary arterial inflammation in the aorta (r=0.51; P=0.001).
There are several important findings from this study that are novel and of interest to understanding arterial inflammation. First, in patients who had high-risk plaque features in the coronary arteries by coronary CT angiography, the authors observed the greatest reduction of arterial inflammation both within the LMCA and in extracoronary arterial inflammation. Indeed, these findings suggest that in patients with high-risk plaque features, there is a potentially greater anti-inflammatory effect of statins. This concept of imaging-guided statin therapy has been demonstrated using coronary artery calcium scoring to guide statin therapy 12, 13 and adds to a body of evidence supporting a personalized medicine approach for allocation of statin therapy. Furthermore, the observation of a relationship between high-risk plaque morphology and arterial inflammation provides further evidence that arterial inflammation by fluorodeoxyglucose PET CT can serve as a reliable surrogate marker of coronary atherosclerosis at high risk for future rupture. These findings support the notion that fluorodeoxyglucose PET CT imaging provides a reliable and accurate surrogate marker for future cardiovascular events that may aid in evaluation of emerging interventions in cardiovascular disease trials. In a recent review, 14 the author reviews 5 classes of drugs that have been studied with imaging arterial inflammation before and after therapy, as well as have executed large clinical outcome trials. Only in those therapies where arterial inflammation improved was there a benefit in clinical outcome studies. Therefore, this concordance between improvement in arterial inflammation and future cardiovascular events provides valuable preliminary data when planning large outcome studies.
There are important limitations that should be considered about the study. The patients were part of an ongoing clinical trial, and there was attrition of patient data because of image quality that may bias the results if those patients had more severely diseased vessels. Furthermore, the authors excluded those with target/background ratio of <1.6 so these results should not be generalized to those with milder arterial inflammation. Finally, the most significant limitation of the study relates to the actual imaging of the LMCA inflammation. Similar to a student being told to suspend disbelief in a creative writing class, one must first take the plunge and believe that fluorodeoxyglucose PET CT can reliably assess LMCA inflammation, given that it is a small structure difficult to resolve with the current spatial resolution of PET CT. However, it should be noted that the study limited measures to the LM, a structure that does not take an epicardial course and thus is further from myocardial activity, and is subject to less motion during the cardiac cycle (relative to more distant coronary segments). Nonetheless, the inability of fluorodeoxyglucose -PET to reliably measure activity beyond the most proximal segment of the coronary tree represents a major limitation of this approach. Notwithstanding these limitations, the study adds to the growing, strong body of work demonstrating extracoronary arterial inflammation by fluorodeoxyglucose PET CT provides a reliable surrogate marker to understand the effect of cardiovascular interventions on vascular outcomes, including coronary artery disease.
